Allergy Vaccine Successful

27-Jan-2017 - Biomay announced that a second Phase IIb study has been successfully completed with its third generation grass pollen allergy vaccine BM32. The study was designed to demonstrate the optimal dose regimen to induce an allergen-specific IgG immune response. Correlation of the immunological effects ...

Selective IgE immune apheresis hits market

Help for patients with IgE-mediated diseases

10-Sep-2015 - Biomay AG announced that CE mark designation has been achieved for a medical device indicated for the treatment of IgE-mediated diseases, which has been co-developed by the company together with a medical device manufacturer. The product is an immune apheresis column which contains a single chain ...

Positive Phase IIB data for Biomay's grass pollen allergy vaccine

09-Jun-2015 - Biomay announced that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona, Spain. The study, which was completed in 2014, convincingly provided clinical proof of concept for this first of kind ...

VTU Technology and Biomay Have Signed License Agreement

Biomay to apply VTU Pichia strains for the production of recombinant allergens

22-May-2015 - VTU Technology and Biomay, two Austrian biotech companies, announced, that they have entered into a licensing agreement for the production of recombinant allergens. VTU Technology grants Biomay access to VTU´s Pichia pastoris protein expression technology. Biomay will apply industrial Pichia ...

Biomay reports positve Phase IIB data with grass pollen allergy vaccine

30-Jan-2015 - Biomay announced that a landmark Phase IIb study has been successfully completed with its 3rd generation grass pollen allergy vaccine BM32. The study was designed to show sustained alleviation of allergy symptoms over two consecutive grass pollen seasons.It was observed that the ...

Biomay's grass pollen allergy vaccine shows efficacy in phase IIa trial

15-Jun-2012 - Biomay AG announced promising results from a First-in-Man Phase IIa trial with its allergy vaccine BM32. The vaccine significantly reduced allergy-related nasal symptoms in a study group of 70 patients suffering from grass pollen allergy. The environmental challenge study also showed that BM32 ...